MAPT and Alzheimer disease: This lower level of PE-Pls is, however, not limited to regions of the brain where there is morphological damage but is even seen in the levels of PE-Pls in circulation, which correlated with a characteristic AD biomarker, i.e., an increased level of the protein Tau in the cerebrospinal fluid (Kling et al., 2020).